39 related articles for article (PubMed ID: 38355781)
1. Improving Outcomes with Chemoradiotherapy in the Mucosal Squamous Cell Carcinomas - Immune Checkpoint Inhibition and Broken Promises.
Samuel R; Samson A; Gilbert DC
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):764-768. PubMed ID: 37743210
[No Abstract] [Full Text] [Related]
2. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
3. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.
Cox SJ; O'Cathail SM; Coles B; Crosby T; Mukherjee S
Curr Oncol Rep; 2017 Jan; 19(1):7. PubMed ID: 28213876
[TBL] [Abstract][Full Text] [Related]
4. Comment on "Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study".
Gronnier C
Ann Surg Oncol; 2024 May; 31(5):2815-2817. PubMed ID: 38355781
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
[No Abstract] [Full Text] [Related]
6. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
7. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].
Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
[No Abstract] [Full Text] [Related]
9. Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
Ann Surg Oncol; 2023 Sep; 30(9):5885-5894. PubMed ID: 37264286
[TBL] [Abstract][Full Text] [Related]
10. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.
Kitagawa Y; Ishihara R; Ishikawa H; Ito Y; Oyama T; Oyama T; Kato K; Kato H; Kawakubo H; Kawachi H; Kuribayashi S; Kono K; Kojima T; Takeuchi H; Tsushima T; Toh Y; Nemoto K; Booka E; Makino T; Matsuda S; Matsubara H; Mano M; Minashi K; Miyazaki T; Muto M; Yamaji T; Yamatsuji T; Yoshida M
Esophagus; 2023 Jul; 20(3):343-372. PubMed ID: 36933136
[No Abstract] [Full Text] [Related]
11. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R; Alsina M; Cervantes A; Leong T; Lordick F; Nilsson M; van Grieken NCT; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):992-1004. PubMed ID: 35914638
[No Abstract] [Full Text] [Related]
12. CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison.
Donlon NE; Moran B; Kamilli A; Davern M; Sheppard A; King S; Donohoe CL; Lowery M; Cunningham M; Ravi N; Mueller C; Cools-Lartigue J; Ferri L; Reynolds JV
Ann Surg; 2022 Nov; 276(5):792-798. PubMed ID: 35876385
[TBL] [Abstract][Full Text] [Related]
13. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
Faron M; Cheugoua-Zanetsie AM; Thirion P; Nankivell M; Winter K; Cunningham D; Van der Gaast A; Law S; Langley R; de Vathaire F; Valmasoni M; Mauer M; Roth J; Gebski V; Burmeister BH; Paoletti X; van Sandick J; Fu J; Ducreux M; Blanchard P; Tierney J; Pignon JP; Michiels S;
Eur J Cancer; 2021 Nov; 157():278-290. PubMed ID: 34555647
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
